ReviewClinical trials (London, England)2024

Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.

Yong Zang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.